Objectives
Develop a robust list and net pricing strategy for the launch of PRODUCT X, taking into account market-by-market funding mechanisms, clinical value proposition, opportunities for differentiation, and the evolving clinical and access landscape in ALK+ non-small cell lung cancer (NSCLC) .
Scope
Methodology
Critically assess the clinical and market access landscape of ALK+ NSCLC, understanding the sequencing, unmet need, funding mechanisms, etc. for existing products. Engage payer and key opinion leader (KOL) expert stakeholders to identify potential opportunities and challenges for PRODUCT X. Synthesize findings to deliver a comprehensive market-by-market list and net launch pricing strategy and recommend an optimal launch strategy.
Deliverables
- In-depth interview (IDI) moderator guide and exhibits
- Primary research findings and insights
- Detailed pricing recommendations by market
- Strategic global and local guidance to support pricing and market access
Illustrative Outputs
Impact
CBP provided detailed final pricing and market access guidance with risk mitigation strategies outlined at both a global and local level that allowed for speed to access in a highly competitive space.